fda warning compounded semaglutide october 2025 Troubling Findings in Study of GLP-1 Compounders Compounded "semaglutide" is not FDA-approved

doi: 10.1152/ajpgi.00462.2011 78

Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance

Cell culture reagents were purchased from Gibco-Invitrogen (Paisley, United Kingdom) and Sigma-Aldrich (Poole, United Kingdom)

Patients should maintain realistic expectations: while overall body contour may improve with weight loss, cellulite appearance may persist or change unpredictably

The American Gastroenterological Association and American Diabetes Association have published statements noting that GLP-1 use after pancreatitis may be considered on a case-by-case basis, with stronger caution for those with chronic pancreatitis or recurrent episodes